Dennis Podlesak

CIK: 0001314595

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (40.0%)

Position reduction

Option Exercises (M)4 (40.0%)

Derivative conversions

Awards (A)2 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SNDX

Syndax Pharmaceuticals Inc

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

SNDX
Syndax Pharmaceuticals Inc
Oct 29, 2026
Sale(S)
Direct
8K shares at avg. $14.21$114K
SNDX
Syndax Pharmaceuticals Inc
Oct 29, 2026
Exercise(M)
Direct
8K shares at avg. $11.81$94K
SNDX
Syndax Pharmaceuticals Inc
Feb 4, 2026
Award(A)
Direct
48K shares-
SNDX
Syndax Pharmaceuticals Inc
Aug 18, 2025
Exercise(M)
Direct
19.2K shares at avg. $7.20$138K
SNDX
Syndax Pharmaceuticals Inc
Aug 18, 2025
Sale(S)
Direct
19.2K shares at avg. $15.84$304K
SNDX
Syndax Pharmaceuticals Inc
Aug 15, 2025
Exercise(M)
Direct
19.2K shares at avg. $7.20$138K
SNDX
Syndax Pharmaceuticals Inc
Aug 15, 2025
Sale(S)
Direct
19.2K shares at avg. $15.54$298K
SNDX
Syndax Pharmaceuticals Inc
Aug 14, 2025
Exercise(M)
Direct
19.2K shares at avg. $7.20$138K
SNDX
Syndax Pharmaceuticals Inc
Aug 14, 2025
Sale(S)
Direct
19.2K shares at avg. $14.19$273K
SNDX
Syndax Pharmaceuticals Inc
Feb 5, 2025
Award(A)
Direct
50K shares-

		Type	Shares	Price		Ownership
Oct 29, 2026	SNDX Syndax Pharmaceuticals Inc	Sale(S)	8,000	$14.21	$113,716	Direct
Oct 29, 2026	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	8,000	$11.81	$94,480	Direct
Feb 4, 2026	SNDX Syndax Pharmaceuticals Inc	Award(A)	48,000	-	$0	Direct
Aug 18, 2025	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	19,200	$7.20	$138,240	Direct
Aug 18, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	19,200	$15.84	$304,170	Direct
Aug 15, 2025	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	19,200	$7.20	$138,240	Direct
Aug 15, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	19,200	$15.54	$298,408	Direct
Aug 14, 2025	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	19,200	$7.20	$138,240	Direct
Aug 14, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	19,200	$14.19	$272,521	Direct
Feb 5, 2025	SNDX Syndax Pharmaceuticals Inc	Award(A)	50,000	-	-	Direct

1-10 of 10 transactions

About Podlesak Dennis

Podlesak Dennis (SEC CIK 0001314595) files insider reports with the SEC as Director of Syndax Pharmaceuticals Inc (SNDX).

Signal8 holds 4 ownership filings by Podlesak Dennis, all Form 4s, filed between Feb 7, 2025 and Oct 30, 2026. Those filings report 10 transactions, from Feb 5, 2025 to Oct 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Podlesak Dennis's filings is in NEW YORK, NY.

Recent filings by Podlesak Dennis

Oct 29, 2026: Open-market sale of SNDX shares (Form 4, code S).
Oct 29, 2026: Option exercise of SNDX shares (Form 4, code M).
Feb 4, 2026: Grant or award of SNDX shares (Form 4, code A).
Aug 18, 2025: Option exercise of SNDX shares (Form 4, code M).
Aug 18, 2025: Open-market sale of SNDX shares (Form 4, code S).

Other insiders filing for Syndax Pharmaceuticals Inc (SNDX)

Metzger Michael A, Chief Executive Officer
Botwood Nicholas A.J., Head of R&D, CMO
Goldan Keith A., Chief Financial Officer
Jarrett Jennifer, Director
Huber Martin H. Jr., Director
Rizo Aleksandra, Director

How to read Form 4 transaction codes